Security Snapshot

C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CCCC) Institutional Ownership

CUSIP: 12529R107

13F Institutional Holders and Ownership History from Q4 2020 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

112

Shares (Excl. Options)

104.56MFull value: 104,558,355 · shares · 30 Sep 2026

Price

$3.33

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+14,814,394
Value change
+$45,259,139
Number of holders
112
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
137,921,939
SEC-reported price per share
$2.98
Insider filing price
$2.98
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • CCCC - C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 12529R107.
  • 112 institutions reported positions in Q3 2026.
  • 11 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 147 to 112 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $547.9MFull value: $547,897,453 · USD · 30 Jun 2026
    to
    $348.12MFull value: $348,117,182 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 112 institutions filings for Q3 2026.

Open SEC evidence

Security key

12529R107

13F reference period

Q3 2026

13F holders

112

13D/G owners

11

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
11
Security
CCCC
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Sirenia Capital Management LP 9.9% $59,702,700 23,505,000 Sirenia Capital Management LP 31 Mar 2026
Lynx1 Capital Management LP 10% +38% $66,167,634 +$35,716,644 15,423,691 +117% Lynx1 Capital Management LP 30 Jun 2026
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $40,689,731 +$6,766,316 13,654,272 +20% RA Capital Management, L.P. 30 Sep 2026
Soleus Capital Master Fund, L.P. 10% $19,791,153 10,361,860 Soleus Capital Master Fund, L.P. 31 Dec 2025
Squadron Capital Management LLC 7.9% +14% $32,363,214 +$7,055,214 9,718,683 +28% Squadron Master Fund LP 30 Sep 2026
MORGAN STANLEY 8% -14% $38,017,989 -$481,291 8,862,002 -1.3% Morgan Stanley 30 Jun 2026
BlackRock, Inc. 6.9% +147% $35,860,491 +$27,657,108 7,678,906 +337% BlackRock, Inc. 30 Jun 2026
Bain Capital Life Sciences Fund II, L.P. 6.2% $13,453,200 6,060,000 BCLS II Equity Opportunities, LP 17 Oct 2025
WASATCH ADVISORS LP 6.8% -34% $10,773,085 -$5,817,712 4,852,741 -35% Wasatch Advisors LP 30 Sep 2025
ORBIMED ADVISORS LLC 1% -80% $1,687,550 -$5,127,991 883,534 -75% OrbiMed Capital LLC 31 Dec 2025
Point72 Asset Management, L.P. 0.2% -97% $429,504 -$57,095,520 169,096 -99% Point72 Asset Management, L.P. 31 Mar 2026
As of 30 Sep 2026, 112 institutional investors reported holding
104.56MFull value: 104,558,355 · shares · 30 Sep 2026
shares of C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CCCC). This represents 76% of the company’s total
137.92MFull value: 137,921,939 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
61%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Squadron Capital Management LLC 6.8% 9,318,683 9.2% $31,031,214
RA CAPITAL MANAGEMENT, L.P. 5.9% 8,194,779 0.27% $27,288,614
Lynx1 Capital Management LP 5.5% 7,530,915 3.9% $25,077,947
Bain Capital Life Sciences Investors, LLC 5.2% 7,171,910 1.6% $23,882,460
GOLDMAN SACHS GROUP INC 3.4% 4,683,379 0% $15,595,652
VANGUARD CAPITAL MANAGEMENT LLC 3.3% 4,581,502 0% $15,256,402
WASATCH ADVISORS LP 3% 4,160,048 0.1% $13,852,960
Boxer Capital Management, LLC 3% 4,150,000 1.2% $13,819,500
TWO SIGMA INVESTMENTS, LP 2.7% 3,746,738 0.01% $12,476,638
SILVERARC CAPITAL MANAGEMENT, LLC 2.5% 3,454,647 1.4% $11,503,975
Soleus Capital Management, L.P. 2.4% 3,357,981 0.4% $11,182,077
STEMPOINT CAPITAL LP 2.4% 3,293,376 2% $10,966,942
BANK OF AMERICA CORP /DE/ 2.1% 2,890,772 0% $9,626,270
GEODE CAPITAL MANAGEMENT, LLC 2% 2,699,545 0% $8,991,069
Qube Research & Technologies Ltd 1.7% 2,397,086 0.01% $7,982,296
STATE STREET CORP 1.6% 2,218,580 0% $7,387,871
Ikarian Capital, LLC 1.4% 1,933,000 1.3% $6,436,890
DIMENSIONAL FUND ADVISORS LP 1% 1,384,966 0% $4,609,336
CONGRESS ASSET MANAGEMENT CO 0.91% 1,256,692 0.03% $4,184,784
RENAISSANCE TECHNOLOGIES LLC 0.88% 1,209,376 0.01% $4,027,222
VANGUARD PORTFOLIO MANAGEMENT LLC 0.79% 1,094,194 0% $3,643,666
Atom Investors LP 0.66% 911,528 0.23% $3,035,388
HighVista Strategies LLC 0.63% 873,277 0.76% $2,908,012
MARSHALL WACE, LLP 0.62% 855,805 0% $2,849,832
VANGUARD FIDUCIARY TRUST CO 0.52% 721,744 0% $2,403,408

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
24
Headline period
Q3 2026
Rows shown
1-24 of 24
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 104,558,355 $348,117,182 +$45,259,139 $3.33 112
2026 Q2 117,679,108 $547,897,453 +$159,817,274 $4.67 147
2026 Q1 84,491,097 $221,300,312 +$11,954,068 $2.63 122
2025 Q4 79,828,313 $152,468,758 +$51,887,612 $1.91 101
2025 Q3 52,538,995 $116,636,299 -$3,450,925 $2.22 96
2025 Q2 54,715,914 $78,242,864 -$14,672,718 $1.43 102
2025 Q1 64,100,740 $102,562,013 -$12,577,745 $1.60 113
2024 Q4 64,400,415 $231,841,449 -$9,805,080 $3.60 113
2024 Q3 64,180,724 $365,858,667 +$21,073,945 $5.70 118
2024 Q2 60,887,928 $281,302,982 +$5,545,189 $4.62 114
2024 Q1 58,201,499 $475,505,218 +$93,890,692 $8.17 104
2023 Q4 47,001,017 $265,585,658 +$85,422,229 $5.65 91
2023 Q3 34,671,251 $64,488,483 -$134,435 $1.86 82
2023 Q2 34,220,399 $94,120,957 -$9,383,233 $2.75 96
2023 Q1 37,418,446 $117,492,869 -$15,156,032 $3.14 117
2022 Q4 39,224,213 $231,404,815 -$9,766,681 $5.90 113
2022 Q3 39,456,577 $346,000,579 -$2,524,371 $8.77 115
2022 Q2 39,425,650 $297,247,580 -$39,977,861 $7.54 111
2022 Q1 37,306,180 $904,604,832 +$6,530,479 $24.26 120
2021 Q4 35,893,940 $1,154,835,979 +$16,687,200 $32.20 115
2021 Q3 34,491,766 $1,542,710,693 +$110,759,163 $44.68 110
2021 Q2 31,945,852 $1,209,520,921 +$259,679,873 $37.84 106
2021 Q1 25,097,387 $926,788,055 +$90,401,887 $36.99 83
2020 Q4 22,706,689 $743,535,975 +$718,564,975 $33.13 75
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .